Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide - Calagua, Carla; Russo, Joshua; Sun, Yue; Schaefer, Rachel; Lis, Rosina; Zhang, Zhenwei; Mahoney, Kathleen; Bubley, Glenn J.; Loda, Massimo; Taplin, Mary-Ellen; Balk, Steven P.; Ye, Huihui (Clinical cancer research, 2017)
Keywords: Abiraterone Acetate - administration & dosage; Acetic acid; Androgens; Antibodies; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis; B7-H1 Antigen - genetics; B7-H1 Antigen - metabolism; Cancer; Cancer surgery; CD8 antigen; Cell death; Deoxyribonucleic acid; Deprivation; DNA; DNA Mismatch Repair; DNA repair; Experimental design; Gene Expression; Health risks; Humans; Immunogenicity; Immunohistochemistry; Leuprolide - administration & dosage; Lymphocytes, Tumor-Infiltrating - immunology; Lymphocytes, Tumor-Infiltrating - metabolism; Male; Minority & ethnic groups; Mismatch repair; MSH2 protein; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Patients; PD-1 protein; PD-L1 protein; Prednisone; Prednisone - administration & dosage; Prostate cancer; Prostatectomy; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; T-Lymphocyte Subsets - immunology; T-Lymphocyte Subsets - metabolism; Tissues; Tumor cells; Tumors